PAINWeek 2012

In a plenary session at PAINWeek 2012, three mental health experts described innovative programs that have been developed to help improve care for patients with chronic pain and psychiatric comorbidities.

A combination of ibuprofen plus a high-dose H2-receptor antagonist such as famotidine may decrease ibuprofen-induced ulcer disease, according to a study presented at PAINWeek 2012.

LAS VEGAS, NV—A meta-analysis presented at PAINWeek 2012 of two OTC doses of ibuprofen showed that 400 mg provided significantly better overall pain relief compared with 200 mg over a 6-hour period.

Theramine, a prescription-only amino acid food product, may offer a safe alternative to traditional pharmaceutical products used to treat chronic back pain, according to a presentation at PAINWeek 2012.

Tapentadol extended-release tablets is efficacious in the management of moderate-to-severe chronic pain associated with diabetic peripheral neuropathy in adults, according study results presented at PAINWeek 2012.

When used in combination with pregabalin and gabapentin, lidocaine 5% patch is well tolerated and safe for postherpetic neuralgia (PHN), according to a presentation at PAINWeek 2012.

Nano-sized drug particle NSAIDs could be effective in the management of pain and warrant further evaluation, according a presentation at PAINWeek 2012.

Oral methylnaltrexone is generally safe and well tolerated in patients with chronic, non-cancer pain and opioid-induced constipation, according to results of a study presented at PAINWeek 2012.

Lidocaine patch 5% is effective and well-tolerated if applied to the face, trunk, or extremities, according to the results of a study in patients with postherpetic neuralgia reported during PAINWeek 2012.